<DOC>
	<DOCNO>NCT00818818</DOCNO>
	<brief_summary>This study design evaluate effect low dos pentavalent antimony ( meglumine antimoniate ) treat cutaneous leishmaniasis ulcer patient older 65 year . The hypothesis old patient may positive response lower dose pentavalent antimony , avoid frequent adverse event observed standard dose . The design open uncontrolled trial enrol 20 patient infected parasite Leishmania braziliensis endemic area State Bahia , Brazil . The endpoint cure therapeutic failure evaluate third month follow-up treatment avoid impact spontaneous cure confound factor .</brief_summary>
	<brief_title>Low-dose Pentavalent Antimony Treatment Cutaneous Leishmaniasis Old Age Patients</brief_title>
	<detailed_description />
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Cutaneous</mesh_term>
	<mesh_term>Meglumine antimoniate</mesh_term>
	<criteria>Age &gt; 65 year Permanent residence endemic area Availability caregiver dependent patient Mucosal disease cause leishmaniasis Disseminated cutaneous disease Severe cardiac , renal hepatic disorder Active cancer Active tuberculosis Leprosy HIV positive Total bilirubin &gt; 1.5mg/dL Urea creatinin &gt; 1.5 time upper normal level Alkaline phosphatase aminotransferases &gt; 2.5 time upper normal level Lipase amylase &gt; 1.5 upper normal level Hemoglobin &lt; 5 g/dL</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Leishmaniasis</keyword>
	<keyword>Cutaneous leishmaniasis</keyword>
	<keyword>Leishmania braziliensis</keyword>
	<keyword>Pentavalent antimonial</keyword>
	<keyword>Glucantime</keyword>
</DOC>